Chemical Biology of Regulatory Mechanisms, IBioBA-CONICET-Partner Institute of the Max Planck Society, Godoy Cruz 2390, Buenos Aires, Argentina.
Internal Medicine I, Frankfurt University Hospital, Theodor-Stern-Kai 7, Frankfurt am Main, Germany.
ChemMedChem. 2020 Sep 16;15(18):1682-1690. doi: 10.1002/cmdc.202000368. Epub 2020 Aug 11.
Angiotensin converting enzyme 2 (ACE2) is the human receptor that interacts with the spike protein of coronaviruses, including the one that produced the 2020 coronavirus pandemic (COVID-19). Thus, ACE2 is a potential target for drugs that disrupt the interaction of human cells with SARS-CoV-2 to abolish infection. There is also interest in drugs that inhibit or activate ACE2, that is, for cardiovascular disorders or colitis. Compounds binding at alternative sites could allosterically affect the interaction with the spike protein. Herein, we review biochemical, chemical biology, and structural information on ACE2, including the recent cryoEM structures of full-length ACE2. We conclude that ACE2 is very dynamic and that allosteric drugs could be developed to target ACE2. At the time of the 2020 pandemic, we suggest that available ACE2 inhibitors or activators in advanced development should be tested for their ability to allosterically displace the interaction between ACE2 and the spike protein.
血管紧张素转换酶 2(ACE2)是与人冠状病毒刺突蛋白相互作用的人类受体,包括导致 2020 年冠状病毒病(COVID-19)大流行的冠状病毒。因此,ACE2 是一种潜在的药物靶点,可以破坏人类细胞与 SARS-CoV-2 的相互作用以消除感染。人们还对抑制或激活 ACE2 的药物感兴趣,即用于心血管疾病或结肠炎。结合在替代部位的化合物可以变构影响与刺突蛋白的相互作用。本文综述了 ACE2 的生化、化学生物学和结构信息,包括最近的全长 ACE2 的 cryoEM 结构。我们得出结论,ACE2 非常具有动态性,并且可以开发变构药物来靶向 ACE2。在 2020 年大流行期间,我们建议应测试处于高级开发阶段的可用 ACE2 抑制剂或激活剂,以确定它们是否能够变构置换 ACE2 与刺突蛋白之间的相互作用。